Company intelligence / Profile preview

Yuezhou Pharmaceutical

Taizhou, Zhejiang, China

Ownership: Private
Employees: ~2000
Development stage: Other

Overview

Jiuzhou Pharmaceutical is a leading China-based CDMO and API manufacturer for global pharma and biotech, with a robust commercial business in major APIs (carbamazepine, oxcarbazepine, ketoprofen, gliclazide) and 26+ clinical programs (2025). The company operates across pre-clinical, clinical, and commercial stages as a major producer for pharma multinationals, and maintains strong regulatory track records (FDA, EDQM).

Therapeutic areas: EndocrinologyRheumatologyPsychiatryInfectious DiseasesOncologyNeurology
Modalities: Small moleculePeptidesPeptide-drug conjugateSmall molecule-drug conjugateRadiopharmaceuticalBiologic
Industry: Contract Manufacturing Organization

Partnerships

NovartisRocheDaiichi SankyoZoetisHUTCHMEDBetta PharmaceuticalsHaihe BiopharmaLuye Pharma

Beyond the preview

Go deeper on Yuezhou Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yuezhou Pharmaceutical.

Explore the full profile